The privately-held German biotechnology company specializes in immunology and T-cell diagnostics, offering custom-made services for cell-based bioactivity and quality tests for pharmaceutical agents. Lophius Biosciences' proprietary T-activation® and Reverse T Cell Technology platforms allow for efficient stimulation of immune effector cells to accurately measure cell-mediated immunity, differentiate between active and memory T cells, and identify patients with contagious active diseases and latent infections. The company's core program addresses an unmet clinical need in tuberculosis (TB) detection and is advancing biomarker combinations to differentiate between active TB disease and latent TB infection. They also offer a clinically validated CE marked diagnostic kit to individualize transplant patient management by personalized CMV disease risk stratification.